Evidence map›Paper›PMID 39625479›Full record

ArticleCellular and molecular life sciences : CMLS2024

Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors.

Karthikeyan Subbarayan, Ahmed Al-Samadi, Helene Schäfer, Chiara Massa, Tuula Salo, Katharina Biehl, Christoforos K Vaxevanis, Kamatchi Ulagappan, Wafa Wahbi, Matthias Reimers and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karthikeyan SubbarayanMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Ahmed Al-SamadiInstitute of Dentistry, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Joensuu, Finland.
Helene SchäferMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Chiara MassaMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Tuula SaloDepartment of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.
Katharina BiehlMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Christoforos K VaxevanisMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Kamatchi UlagappanMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Wafa WahbiDepartment of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.
Matthias ReimersMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany.
Felix DrexlerCharité, Institute of Virology, Berlin, Germany.
Andres Moreira-SotoCharité, Institute of Virology, Berlin, Germany.
Michael BachmannInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Barbara SeligerMedical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112, Halle (Saale), Germany. immunologie@uk-halle.de.ORCID https://orcid.org/0000-0002-5544-4958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensensin-converting enzyme-2 (ACE2) is a receptor for SARS-CoV-2, allowing the virus to enter cells. Although tumor patients infected by SARS-CoV-2 often have a worse outcome, the expression, function and clinical relevance of ACE2 in tumors has not yet been thoroughly analyzed. In this study, RNA sequencing (RNA-seq) data from tumors, adjacent tissues and whole blood samples of COVID-19 patients from genome databases and from tumor cell lines and endothelial cells infected with different SARS-CoV-2 variants or transfected with an ACE2 expression vector (ACE2

Indexed as

Angiotensin-Converting Enzyme 2COVID-19NeoplasmsSARS-CoV-2Tumor MicroenvironmentB7-H1 AntigenCell Line, TumorHumansImmune Checkpoint InhibitorsInterferonsProgrammed Cell Death 1 ReceptorACE2 protein, humanAngiotensin-Converting Enzyme 2B7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsInterferonsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorImmune escapeImmune responseImmunotherapySARS-CoV-2Tumors

Identifiers

PMID39625479
PMCPMC11615173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.